Cutaneous leishmaniasis is treated with a surprisingly wide range of therapies, from injections directly into the skin lesion to oral pills, topical creams, and even localized heat, but no single treatment works best for every case. The choice depends heavily on which species of the Leishmania parasite caused the infection, where on the body the lesion sits, how many lesions there are, and whether the patient has a healthy immune system. With an estimated incidence of over 1.5 million cases per year across 82 countries, this is one of the world’s most common neglected tropical diseases, and its treatment landscape is messier than you might expect.
Why Species Identification Comes First
Before choosing a treatment, clinicians ideally want to know which Leishmania species is responsible. Different species respond differently to the same drug, and some carry a risk of spreading to the mucous membranes of the nose and mouth, which changes the urgency and aggressiveness of treatment entirely. Species determination is considered critical for optimal management, yet the DNA-based techniques that allow relatively easy identification are hard to implement in the resource-limited settings where most cases occur.1PubMed Central. Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments
In practice, this means treatment is often guided by geography as a proxy. If you picked up the infection in the Middle East or North Africa, the species is most likely L. major or L. tropica, which rarely involve mucous membranes. Infections acquired in Latin America, on the other hand, may involve L. braziliensis or L. guyanensis, species that carry a higher risk of mucosal spread. A European study of 459 patients found that New World infections were more frequently ulcerative, larger on average, and more likely to affect the lower limbs, while Old World infections were more often on the face and tended to evolve more slowly.2PLOS Neglected Tropical Diseases. Clinical diversity and treatment results in Tegumentary Leishmaniasis: A European clinical report in 459 patients These differences directly shape which drug gets prescribed. When a clinic in Switzerland began tailoring treatment to the identified species, outcomes improved and one drug recommendation was changed entirely after evidence of treatment failures emerged with a previously favored option.3PubMed. Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment
Newer diagnostic tools are trying to close the gap. A colorimetric assay targeting single nucleotide fingerprints in a conserved parasite gene now allows precise early differentiation between species associated with mucocutaneous and purely cutaneous disease. The goal is to enable personalized treatment plans that avoid exposing patients to toxic therapies when a milder approach would suffice, and to catch mucocutaneous-risk species before irreversible mucosal damage occurs.4PubMed. A novel colorimetric assay for early differentiation of mucocutaneous and cutaneous leishmaniasis via species-specific identification
Pentavalent Antimonials, the Traditional First-Line Drugs
For decades, the backbone of cutaneous leishmaniasis treatment has been pentavalent antimonials, specifically sodium stibogluconate and meglumine antimoniate. These remain the first-choice drugs in many treatment guidelines worldwide. They work, but they come with real drawbacks: the treatment is expensive, can cause serious adverse effects including cardiac toxicity and liver or pancreatic inflammation, and is not always effective.5PubMed Central. Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review For systemic use, the drugs require daily injections for weeks, typically administered in a clinical setting where side effects can be monitored.
A major question with antimonials is whether they should be given systemically (injected into a muscle or vein to circulate through the whole body) or intralesionally (injected right into the skin sore). A meta-analysis comparing intralesional to systemic meglumine antimoniate found that intralesional therapy produced roughly 14% more complete cures and had substantially fewer adverse events, including fewer severe reactions, fewer laboratory abnormalities, and fewer heart-rhythm changes on electrocardiograms.6Current Tropical Medicine Reports. Efficacy and Safety in the Treatment of Patients with Cutaneous Leishmaniasis of Intralesional Compared to Intramuscular or Intravenous Administration of Meglumine Antimony: a Systematic Review and Meta-Analysis A retrospective European study of imported cases found intralesional treatment achieved a cure rate of about 86% against L. tropica, compared with 67% for systemic treatment of the same species.7PubMed. Treatment outcome of imported cutaneous leishmaniasis among travelers and migrants infected with Leishmania major and Leishmania tropica: a retrospective study in European centers 2013 to 2019
The catch is that intralesional injections only make sense for a limited number of small, accessible skin lesions. If you have dozens of sores, or if the infection is caused by a species with mucocutaneous risk, systemic treatment is usually necessary regardless of the side-effect profile.
Miltefosine, the Oral Alternative
Miltefosine is the only oral drug approved for leishmaniasis, which makes it a game-changer for patients who cannot tolerate injections or who lack access to clinical facilities for daily parenteral treatment. Given daily for about four weeks, miltefosine has been reported to cure around 94% of patients in supervised settings.8PubMed Central. Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management An open-label study from Balochistan found a complete clinical response in about 93% of patients with no significant changes in blood work before and after treatment.9PubMed Central. Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan
Its main limitations are practical rather than pharmacological. Miltefosine causes birth defects, so pregnancy must be avoided during treatment and for two months afterward. The other concern is adherence: because it is an oral pill taken at home, patients sometimes stop early or skip doses. Incomplete courses do not just reduce the chances of cure; they create conditions where drug-resistant parasites can emerge, a worry that looms large given how few drugs are available for this disease in the first place.10PubMed Central. Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management Gastrointestinal side effects like nausea, vomiting, and diarrhea are common but generally manageable.
Topical Paromomycin for Uncomplicated Lesions
The appeal of a cream you can smear on a skin sore and treat at home is obvious, and paromomycin, an aminoglycoside antibiotic, is the topical formulation with the most evidence behind it. A randomized placebo-controlled trial testing a 15% paromomycin-Aquaphilic formulation against L. braziliensis found that about 78% of treated patients were cured, with most of those cures evident within a month after the end of therapy.11Clinical Infectious Diseases. Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis Cutaneous Leishmaniasis: A Randomized, Placebo-controlled Trial
The problem is that paromomycin has five ionizable amino groups that make it difficult for the drug to penetrate deep enough into the skin through passive absorption alone. Even when formulated at high drug concentrations, its efficacy has been described as controversial. Newer delivery approaches, including iontophoresis (using a mild electrical current to push the drug deeper) and hydrogel formulations, have shown they can deliver effective drug amounts to deeper skin layers while using far less drug than conventional ointments.12PubMed. Enhanced topical paromomycin delivery for cutaneous leishmaniasis treatment: Passive and iontophoretic approaches These are not yet standard clinical practice, but they represent the most active area of topical treatment research.
Topical treatments in general are attracting interest precisely because the available systemic drugs are toxic, painful to administer, and require hospital-level infrastructure to manage side effects. A treatment that could be applied at home would reduce costs for both patients and health systems and improve the chances that people actually complete the full course.13PubMed Central. Cutaneous leishmaniasis: epidemiology, treatment access and translational challenges of topical therapies
Heat Therapy and Cryotherapy
Physical destruction of the lesion using heat or cold is among the oldest and most practical approaches, especially in settings where drugs are scarce or supply chains unreliable. Radiofrequency-induced heat therapy applies a temperature of 50°C to the lesion for 30 seconds in a single session. A randomized trial comparing this to weekly intralesional sodium stibogluconate injections for L. donovani infections found that heat therapy produced significantly higher cure rates at 8 and 10 weeks, and comparable rates by 12 weeks, with no major adverse events. The researchers concluded it was noninferior to the standard drug regimen, with added benefits of convenience and cost-effectiveness.14PubMed Central. Efficacy, Safety and Cost-Effectiveness of Thermotherapy in the Treatment of Leishmania donovani–Induced Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial
Results vary by species and setting, however. A trial against L. major found that heat therapy cured about 48% of patients at two months, compared with 54% for intravenous sodium stibogluconate, a difference that was not statistically significant. When analyzed by individual lesion rather than by patient, the heat group actually performed better, with 73% of lesions cured versus 59%.15PLoS Neglected Tropical Diseases. A Randomized Controlled Trial of Local Heat Therapy Versus Intravenous Sodium Stibogluconate for the Treatment of Cutaneous Leishmania major Infection The takeaway is that heat therapy is a reasonable option for uncomplicated single lesions, especially where a single clinic visit is all that is feasible.
Cryotherapy with liquid nitrogen is widely used but, on its own, appears to have limited effectiveness. A comparative study found that cryotherapy alone produced a response in only about 18% of patients, while combining cryotherapy with intralesional meglumine antimoniate achieved 100% efficacy.16Journal of Postgraduate Medical Institute. Efficacy of Combined Intralesional Meglumine Antimoniate and Cryotherapy Versus Cryotherapy Alone for the Treatment of Cutaneous Leishmaniasis Cryotherapy seems to work best as a complement to drug therapy rather than as a standalone treatment.
Liposomal Amphotericin B for Difficult Cases
When first-line treatments fail or cannot be used, liposomal amphotericin B is the main fallback. It is given intravenously, typically in a hospital setting, and tends to be reserved for cases that are severe, widespread, immunosuppressed, or caused by species that resist other drugs. A systematic review and meta-analysis pooling data from 132 studies found a pooled cure rate of about 87% across case series, with a finding that over 80% of individual case reports also resulted in cure. The downside is toxicity: roughly 41% of case-series patients experienced an adverse reaction.17PubMed Central. Intravenous Liposomal Amphotericin B Efficacy and Safety for Cutaneous and Mucosal Leishmaniasis: A Systematic Review and Meta-analysis Kidney toxicity, infusion-related fevers, and electrolyte imbalances are the main concerns. This is effective medicine but not comfortable medicine.
Photodynamic Therapy
Photodynamic therapy applies a light-sensitive chemical to the lesion and then illuminates it with a specific wavelength of light, generating reactive oxygen species that kill the parasites. A systematic review found that this approach is effective and safe for cutaneous leishmaniasis, with side effects that are mild and temporary: pain or tingling during the light exposure, followed by redness, pigmentation changes, and swelling afterward.18PubMed. Photodynamic therapy in management of cutaneous leishmaniasis: A systematic review Protocols varied widely across studies in terms of the photosensitizer used, how long it was left on, the light source, and the number of sessions, which makes it hard to give a single cure-rate figure. This remains a niche approach used primarily when other options are unavailable or have failed, but it is gaining attention as a low-toxicity local treatment.
Treatment in Children
Children make up a large share of cutaneous leishmaniasis cases in endemic areas, yet most treatment studies enroll adults. A systematic review of interventions specifically studied in children found that miltefosine and meglumine antimoniate were the most frequently evaluated drugs for New World infections, with miltefosine curing 68–83% and meglumine antimoniate curing 17–69%. For Old World infections, one study found intralesional meglumine antimoniate cured about 72% of children, while cryotherapy alone managed only around 42%. Reassuringly, no serious adverse events were reported in any of the pediatric participants across the studies reviewed.19PubMed Central. Interventions to treat cutaneous leishmaniasis in children: A systematic review
A small case series of 10 children treated with oral miltefosine for Old World infections found complete response in 80%, with treatment failure in two cases and only minimal side effects from the medication.20PubMed Central. Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients The evidence is thin enough that pediatric treatment still relies heavily on extrapolation from adult data, which is less than ideal given that children metabolize drugs differently and face different risks from scarring on growing tissue.
Pregnancy, HIV, and Other Complicated Scenarios
Pregnancy creates a treatment dilemma because the most effective systemic drugs are either known to be harmful to the fetus (miltefosine is teratogenic) or carry uncertain risks. A small case series found that local therapies, including paromomycin ointment and intralesional sodium stibogluconate injections, were not associated with birth defects or harm to the fetus. But the sample was too small to draw firm conclusions, and the authors called for larger studies before these local agents can be considered definitively safe during pregnancy.21PubMed Central. Cutaneous Leishmaniasis: Case Series on Pregnancy Outcome In practice, clinicians often try to manage pregnant patients with local treatments when possible and delay systemic therapy until after delivery if the disease is not progressing.
HIV co-infection makes everything harder. The immune suppression caused by HIV allows Leishmania parasites to proliferate more aggressively, and the same drugs that already have significant side effects in healthy people cause even more prominent adverse reactions in HIV-positive patients. Relapses are more frequent, treatment failures more common, and mortality higher.22PubMed Central. Leishmaniasis-HIV coinfection: current challenges Diffuse cutaneous leishmaniasis, a severe form with widespread non-ulcerating lesions across the body, has been reported in HIV-positive patients and is particularly challenging to manage.23PubMed. Diffuse cutaneous leishmaniasis: Co-infection with human immunodeficiency virus (HIV) Antiretroviral therapy to restore immune function is an essential part of the treatment plan in these patients, not just an add-on.
Management in general must be individualized by parasite species, lesion burden and location, immune status, geographic region, and drug availability.24PubMed Central. Cutaneous and Mucocutaneous Leishmaniasis: Perspectives on Immunity, Virulence, and Treatment This is not a disease where a single algorithm covers everyone.
Drug Resistance and Why It Matters
One of the reasons the treatment landscape remains so complicated is that Leishmania parasites have developed resistance to virtually every drug used against them. A genomic review identified specific genetic mutations associated with resistance to pentavalent antimonials, miltefosine, amphotericin B, and paromomycin, involving changes in how parasites take up drugs, metabolize them, and pump them back out of their cells.25PubMed Central. Genomic Insight of Leishmania Parasite: In-Depth Review of Drug Resistance Mechanisms and Genetic Mutations Resistance to antimonials is especially advanced in parts of South Asia, where decades of widespread use have selected for resistant strains.
This creates a vicious cycle. When a drug stops working in a region, clinicians switch to the alternatives, but there are only a handful of alternatives to begin with. The loss of any one of them narrows the options for everyone. Incomplete treatment courses, whether from patients stopping their pills early or from health systems that cannot supply a full course, accelerate the process. It is one of the strongest arguments for developing new drugs and ensuring that the ones currently available are used properly.
What Happens After the Parasite Is Gone
Even successful treatment often leaves behind a scar, and for patients with lesions on the face, the cosmetic and psychological burden can be substantial. Leishmaniasis scars tend to be atrophic, meaning the skin is thinner and depressed compared with the surrounding area. Standard scar-management approaches like silicone sheets and steroid injections have limited effect on this type of scarring. A case report described treating an atrophic scar on the nose with a combination of the patient’s own cultured skin cells, fibroblasts and keratinocytes, injected into and grafted onto the scar surface. Six months later, the scar showed significant improvement in depth and texture with acceptable cosmetic results and no adverse events.26PubMed Central. Treatment of atrophic cutaneous leishmaniasis scar using autologous fibroblasts and keratinocytes (a case report and literature review) This kind of approach is expensive and not widely available, but it illustrates that scar management after leishmaniasis is an active area of interest, especially in regions where facial disfigurement carries social stigma.
Vaccine Research and Therapeutic Immunotherapy
No vaccine against cutaneous leishmaniasis is approved for human use, but the concept of a therapeutic vaccine, one given after infection to boost the immune response and help clear the parasite, is being actively explored. A mouse study using nanoparticle-delivered Leishmania antigens combined with immune-stimulating compounds found that the vaccine effectively shifted the immune response toward the protective arm (Th1 cells), promoted nitric oxide production that kills parasites, and reduced both parasite burden and lesion size.27PubMed. PLGA nanoparticle-delivered Leishmania antigen and TLR agonists as a therapeutic vaccine against cutaneous leishmaniasis in BALB/c mice Mouse results do not translate directly to humans, but the principle is sound: the immune system is already the main reason most people eventually clear cutaneous leishmaniasis on their own, and a vaccine that accelerates that process could reduce scarring and prevent mucosal spread.
The broader hope in the field is that a combination of better diagnostics, topical treatments that actually penetrate the skin effectively, and immunotherapeutic approaches could eventually shift treatment away from the toxic systemic drugs that have dominated for decades. That shift has not happened yet, but the pieces are accumulating.